MedTrace Logo

Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults

NCT03129269 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2026-05-04

No results posted yet for this study

Summary

The current study seeks to examine the prevalence of amyloid pathology, among patients referred to the Toulouse Geriatric Frailty Clinic presenting objective memory impairment. We also aim to fully characterize the clinical progression of frail cognitively impaired patients presenting AD (Alzheimer Disease) pathology vs those who also present a cognitive impairment but do not have AD pathology.

Conditions

  • Frail Elderly

Interventions

PROCEDURE

MRI and PET scan

Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of \[18F\]AV-45 will be injected into each subject in an intravenous bolus.

Sponsors & Collaborators

  • MSDAVENIR

    collaborator UNKNOWN

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Bruno VELLAS, MD, Ph D, Pr · University Hospital, Toulouse

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-02
Primary Completion
2024-06-16
Completion
2024-06-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129269 on ClinicalTrials.gov